氯米帕明与育亨宾单次及稳态药代动力学药物相互作用研究
本研究在15名健康男性中开展前瞻性开放标签单中心药代动力学药物相互作用研究,比较氯米帕明与育亨宾单药及联用时的单次和稳态药代动力学。结果显示稳态育亨宾联用氯米帕明后AUC12几何均值比为137%(90%CI 112-168%),提示临床显著相互作用,可能与CYP2D6竞争性抑制有关,两药联用安全耐受。
要点
- 稳态育亨宾联用氯米帕明后AUC12几何均值比137%,提示临床显著相互作用。
- 稳态氯米帕明联用育亨宾后AUC12几何均值比112%(90%CI 104-120%)。
- 两药单用及联用均安全耐受,未报告重大不良事件。
核心结论
- 氯米帕明与育亨宾联用对稳态育亨宾存在临床显著药物相互作用,可能由氯米帕明竞争性抑制CYP2D6介导的育亨宾代谢所致。
- 按欧洲药品管理局指南,该相互作用可归类为无相互作用(<1.25倍)或轻微(>1.25至<2倍)。
- 鉴于两药作用机制互补且安全性良好,该结果为未来疗效研究奠定基础。
研究设计与样本
- 前瞻性、开放标签、单中心药代动力学药物相互作用研究,纳入15名健康男性受试者。
- 采用非房室分析,评估两药口服单药及联用后的单次和稳态药代动力学。
- 血样采集时间点包括基线、0.5(育亨宾)、1、1.5(育亨宾)、2、3、4、5、6、8、12和24小时(氯米帕明)。
- 多次给药后AUC差异采用80-125%等效性界值判定。
主要发现
- 稳态氯米帕明联用育亨宾 vs 单药AUC12几何均值比为112%(90%CI 104-120%)。
- 稳态育亨宾联用氯米帕明 vs 单药AUC12几何均值比为137%(90%CI 112-168%)。
- 两药单用及联用均安全耐受,未报告重大不良事件。
关键数值与推荐
- 稳态育亨宾联用氯米帕明后AUC12几何均值比137%(90%CI 112-168%),超出80-125%等效性界值。
- 稳态氯米帕明联用育亨宾后AUC12几何均值比112%(90%CI 104-120%),落在80-125%等效性界值内。
- 按欧洲药品管理局指南,相互作用程度分类为无相互作用(<1.25倍)或轻微(>1.25至<2倍)。
临床怎么用
- 临床联用氯米帕明与育亨宾时需关注育亨宾暴露量升高,警惕其不良反应。
- 联用期间可考虑对育亨宾进行剂量调整或监测,具体方案需结合患者情况。
- 该相互作用可能由CYP2D6竞争性抑制介导,CYP2D6慢代谢者或合用其他CYP2D6底物时需额外谨慎。
局限性
- 研究仅纳入15名健康男性受试者,样本量小且未包括女性或患者人群。
- 研究为开放标签设计,未设安慰剂对照。
- 研究仅评估药代动力学相互作用和安全性,未评价临床疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Clomipramine (CLOMI) has shown effectiveness in treating premature ejaculation but is linked to erectile dysfunction and reduced libido. Yohimbine (YOH), by contrast, is effective in treating erectile dysfunction and may improve libido. Combining CLOMI and YOH could potentially leverage the benefits of both drugs. This study aimed to investigate the interactions between these drugs and to evaluate their safety profile. METHODS: A prospective, open-labelled, single-centre, pharmacokinetic (PK) drug-drug interaction study was performed in 15 healthy male subjects. Single-dose and steady-state PK were investigated using noncompartmental analysis after mono- and combination therapy of the 2 orally applied drugs. Plasma sampling was performed at baseline, 0.5 (YOH), 1, 1.5 (YOH), 2, 3, 4, 5, 6, 8, 12 and 24 h (CLOMI). Differences in the area under the curve after multiple dosing (MD) were determined using an equivalence boundary of 80-125%. RESULTS: The geometric mean ratio of the area under the curve up to 12 h for MD CLOMI (combination vs. monotherapy) was 112% (90% confidence interval: 104-120%), whereas for MD YOH this ratio was 137% (90% confidence interval: 112-168%). The study drugs were safe and well tolerated as mono- and combination therapy, with no major adverse events reported. CONCLUSION: A PK assessment of clomipramine and yohimbine indicated a clinically significant drug-drug interaction for MD YOH in combination with CLOMI. This might be explained by competitive, CLOMI-related inhibition of YOH metabolism, probably mediated by cytochrome P450 2D6. However, according to European Medicines Agency guidelines, the effect can be classified as interaction absent (<1,25 fold) or minor (>1.25-<2-fold). Given the complimentary mechanisms of action and the favourable safety profiles, the findings pave the way for future efficacy studies.
引用
- Leutzendorff A, Al Jalali V, Bauer M, et al. Single-dose and steady-state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug-drug interaction study. Br J Clin Pharmacol. 2024. PMID: 39428980. doi:10.1111/bcp.16274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。